The current subanalysis of the PRIZE study may indicate a possibility that febuxostat, a selective XO inhibitor, reduces the MDA‐LDL/LDL‐C ratio, a potential marker of atherosclerosis and oxidative stress, in patients with asymptomatic hyperuricemia and carotid artery atherosclerosis. This evidence concerns the gene XDH and atherosclerosis.